Patrizia Romualdi

List of Publications by Year in Descending Order

126 papers	2,451 citations	25 h-index	43 g-index
131 ext. papers	2,748 ext. citations	4.5 avg, IF	4.6 L-index

#	Paper	IF	Citations
126	Brain-derived neurotrophic factor protects serotonergic neurons against 3,4-methylenedioxymethamphetamine ("Ecstasy") induced cytoskeletal damage.. *Journal of Neural Transmission*, **2022**, 1	4.3	0
125	Targeting the JAK/STAT Pathway: A Combined Ligand- and Target-Based Approach. *Journal of Chemical Information and Modeling*, **2021**, 61, 3091-3108	6.1	0
124	Dysregulation of Nociceptin/Orphanin FQ and Dynorphin Systems in the Extended Amygdala of Alcohol Preferring Marchigian Sardinian (msP) Rats. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
123	Activation of Antioxidant and Proteolytic Pathways in the Nigrostriatal Dopaminergic System After 3,4-Methylenedioxymethamphetamine Administration: Sex-Related Differences. *Frontiers in Pharmacology*, **2021**, 12, 713486	5.6	1
122	An Exploratory Pilot Study of Changes in Global DNA Methylation in Patients Undergoing Major Breast Surgery Under Opioid-Based General Anesthesia. *Frontiers in Pharmacology*, **2021**, 12, 733577	5.6	0
121	Nociceptive behavior and central neuropeptidergic dysregulations in male and female mice of a Fabry disease animal model. *Brain Research Bulletin*, **2021**, 175, 158-167	3.9	0
120	Early-life nicotine or cotinine exposure produces long-lasting sleep alterations and downregulation of hippocampal corticosteroid receptors in adult mice.. *Scientific Reports*, **2021**, 11, 23897	4.9	1
119	Nociceptive responses in melatonin MT receptor knockout mice compared to MT and double MT /MT receptor knockout mice. *Journal of Pineal Research*, **2020**, 69, e12671	10.4	7
118	On the Role of Peripheral Sensory and Gut Mu Opioid Receptors: Peripheral Analgesia and Tolerance. *Molecules*, **2020**, 25,	4.8	3
117	Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?. *Current Medical Research and Opinion*, **2020**, 36, 1015-1024	2.5	4
116	Prescribing opioids to patients with chronic pain: translation of the Opioid Risk Tool into Italian. *Minerva Anestesiologica*, **2020**, 86, 693-695	1.9	2
115	The Therapeutic Potential of Novel Kappa Opioid Receptor-based Treatments. *Current Medicinal Chemistry*, **2020**, 27, 2012-2020	4.3	3
114	NOP receptor antagonism reduces alcohol drinking in male and female rats through mechanisms involving the central amygdala and ventral tegmental area. *British Journal of Pharmacology*, **2020**, 177, 1525-1537	8.6	15
113	Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?. *Current Medical Research and Opinion*, **2020**, 36, I-XVII	2.5	1
112	Safe Use of Opioids in Chronic Kidney Disease and Hemodialysis Patients: Tips and Tricks for Non-Pain Specialists. *Therapeutics and Clinical Risk Management*, **2020**, 16, 821-837	2.9	2
111	The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms. *Biochemical Pharmacology*, **2020**, 182, 114255	6	3
110	Modulation of the Negative Affective Dimension of Pain: Focus on Selected Neuropeptidergic System Contributions. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	6

109	Novel insights on the management of pain: highlights from the Science of Relief meeting. *Pain Management*, **2019**, 9, 521-533	2.3	7
108	Tapentadol for neuropathic pain: a review of clinical studies. *Journal of Pain Research*, **2019**, 12, 1537-1551	2.9	23
107	Pharmacological rationale for tapentadol therapy: a review of new evidence. *Journal of Pain Research*, **2019**, 12, 1513-1520	2.9	14
106	Interplay between the Endogenous Opioid System and Proteasome Complex: Beyond Signaling. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	10
105	Activation of PPAR Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission. *Journal of Neuroscience*, **2019**, 39, 9864-9875	6.6	17
104	Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action. *Minerva Medica*, **2019**, 110, 62-78	2.2	4
103	Short-term withdrawal from repeated exposure to cocaine during adolescence modulates dynorphin mRNA levels and BDNF signaling in the rat nucleus accumbens. *Drug and Alcohol Dependence*, **2019**, 197, 127-133	4.9	5
102	Evidence of a PPAR -mediated mechanism in the ability of Withania somnifera to attenuate tolerance to the antinociceptive effects of morphine. *Pharmacological Research*, **2019**, 139, 422-430	10.2	5
101	Dynorphinergic system alterations in the corticostriatal circuitry of neuropathic mice support its role in the negative affective component of pain. *Genes, Brain and Behavior*, **2019**, 18, e12467	3.6	16
100	Regulation of the Genes Encoding the ppN/OFQ and NOP Receptor. *Handbook of Experimental Pharmacology*, **2019**, 254, 141-162	3.2	3
99	The standardized Withania somnifera Dunal root extract alters basal and morphine-induced opioid receptor gene expression changes in neuroblastoma cells. *BMC Complementary and Alternative Medicine*, **2018**, 18, 9	4.7	11
98	Increased expression of CRF and CRF-receptors in dorsal striatum, hippocampus, and prefrontal cortex after the development of nicotine sensitization in rats. *Drug and Alcohol Dependence*, **2018**, 189, 12-20	4.9	11
97	N/OFQ system in brain areas of nerve-injured mice: its role in different aspects of neuropathic pain. *Genes, Brain and Behavior*, **2017**, 16, 537-545	3.6	11
96	Transcriptional and epigenetic phenomena in peripheral blood cells of monozygotic twins discordant for alzheimer disease, a case report. *Journal of the Neurological Sciences*, **2017**, 372, 211-216	3.2	20
95	Epigenetic Approaches in Neuroblastoma Disease Pathogenesis **2017**,		1
94	Assessment and treatment of breakthrough cancer pain: from theory to clinical practice. *Journal of Pain Research*, **2017**, 10, 2147-2155	2.9	13
93	The challenge of perioperative pain management in opioid-tolerant patients. *Therapeutics and Clinical Risk Management*, **2017**, 13, 1163-1173	2.9	81
92	Mystic Acetaldehyde: The Never-Ending Story on Alcoholism. *Frontiers in Behavioral Neuroscience*, **2017**, 11, 81	3.5	26

91	Alghedon Fentanyl Transdermal System. *Minerva Medica*, **2017**, 108, 169-175	2.2	2
90	From acute to chronic pain: tapentadol in the progressive stages of this disease entity. *European Review for Medical and Pharmacological Sciences*, **2017**, 21, 1672-1683	2.9	25
89	Opioid gene expression changes and post-translational histone modifications at promoter regions in the rat nucleus accumbens after acute and repeated 3,4-methylenedioxy-methamphetamine (MDMA) exposure. *Pharmacological Research*, **2016**, 114, 209-218	10.2	13
88	Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. *Drugs*, **2016**, 76, 1063-5	12.1	3
87	What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. *Drugs*, **2016**, 76, 315-30	12.1	27
86	Cocaine and ethanol target 26S proteasome activity and gene expression in neuroblastoma cells. *Drug and Alcohol Dependence*, **2016**, 161, 265-75	4.9	10
85	Treatment with the neurotoxic A□(25-35) peptide modulates the expression of neuroprotective factors Pin1, Sirtuin 1, and brain-derived neurotrophic factor in SH-SY5Y human neuroblastoma cells. *Experimental and Toxicologic Pathology*, **2016**, 68, 271-6		27
84	Repeated nicotine exposure modulates prodynorphin and pronociceptin levels in the reward pathway. *Drug and Alcohol Dependence*, **2016**, 166, 150-8	4.9	7
83	Fentanyl citrate sublingual formulation (Vellofent□) for quick BTcP hindering. *Minerva Medica*, **2016**, 107, 114-22	2.2	1
82	Peripheral leukocyte expression of the potential biomarker proteins Bdnf, Sirt1, and Psen1 is not regulated by promoter methylation in Alzheimer□ disease patients. *Neuroscience Letters*, **2015**, 605, 44-8	3.3	24
81	A new potent analgesic agent with reduced liability to produce morphine tolerance. *Brain Research Bulletin*, **2015**, 117, 32-8	3.9	11
80	Effects of acute ethanol exposure on class I HDACs family enzymes in wild-type and BDNF(+/-) mice. *Drug and Alcohol Dependence*, **2015**, 155, 68-75	4.9	10
79	Combined exposure to agriculture pesticides, paraquat and maneb, induces alterations in the N/OFQ-NOPr and PDYN/KOPr systems in rats: Relevance to sporadic Parkinson□ disease. *Environmental Toxicology*, **2015**, 30, 656-63	4.2	18
78	Proteasome subunit and opioid receptor gene expression down-regulation induced by paraquat and maneb in human neuroblastoma SH-SY5Y cells. *Environmental Toxicology and Pharmacology*, **2015**, 40, 895-900	5.8	18
77	The prevention of analgesic opioids abuse: expert opinion. *European Review for Medical and Pharmacological Sciences*, **2015**, 19, 4203-6	2.9	2
76	Opioid receptor gene expression in human neuroblastoma SH-SY5Y cells following tapentadol exposure. *Journal of Molecular Neuroscience*, **2014**, 53, 669-76	3.3	9
75	Dynorphin/KOP and nociceptin/NOP gene expression and epigenetic changes by cocaine in rat striatum and nucleus accumbens. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2014**, 49, 36-46	5.5	24
74	Human apolipoprotein E4 modulates the expression of Pin1, Sirtuin 1, and Presenilin 1 in brain regions of targeted replacement apoE mice. *Neuroscience*, **2014**, 256, 360-9	3.9	22

73	Different alcohol exposures induce selective alterations on the expression of dynorphin and nociceptin systems related genes in rat brain. *Addiction Biology*, **2013**, 18, 425-33	4.6	58
72	Modification of anxiety-like behaviors by nociceptin/orphanin FQ (N/OFQ) and time-dependent changes in N/OFQ-NOP gene expression following ethanol withdrawal. *Addiction Biology*, **2013**, 18, 467-79	4.6	35
71	Morphine and fentanyl differently affect MOP and NOP gene expression in human neuroblastoma SH-SY5Y cells. *Journal of Molecular Neuroscience*, **2013**, 51, 532-8	3.3	12
70	The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways in knee osteoarthritis. A randomized open label trial. *Osteoarthritis and Cartilage*, **2013**, 21, 1400-8	6.2	78
69	Selection of nutraceutical compounds as COX inhibitors by molecular topology. *Medicinal Chemistry Research*, **2013**, 22, 3466-3477	2.2	2
68	Ethanol induces epigenetic modulation of prodynorphin and pronociceptin gene expression in the rat amygdala complex. *Journal of Molecular Neuroscience*, **2013**, 49, 312-9	3.3	66
67	[9)-Tetrahydrocannabinol decreases NOP receptor density and mRNA levels in human SH-SY5Y cells. *Journal of Molecular Neuroscience*, **2012**, 46, 285-92	3.3	6
66	Pin1 contribution to Alzheimer's disease: transcriptional and epigenetic mechanisms in patients with late-onset Alzheimer's disease. *Neurodegenerative Diseases*, **2012**, 10, 207-11	2.3	28
65	Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. *Neuropsychopharmacology*, **2012**, 37, 1647-55	8.7	145
64	Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis. *Journal of Ethnopharmacology*, **2011**, 133, 1033-8	5	17
63	Regulation of opioid gene expression in the rat brainstem by 3,4-methylenedioxymethamphetamine (MDMA): role of serotonin and involvement of CREB and ERK cascade. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2011**, 383, 169-78	3.4	10
62	Ethanol and acetaldehyde exposure induces specific epigenetic modifications in the prodynorphin gene promoter in a human neuroblastoma cell line. *FASEB Journal*, **2011**, 25, 1069-75	0.9	33
61	Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease. *Movement Disorders*, **2010**, 25, 1723-32	7	34
60	Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats. *Neuropharmacology*, **2009**, 56, 761-7	5.5	22
59	Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. *Neuropsychopharmacology*, **2008**, 33, 2760-71	8.7	254
58	Effects of the selective neurotensin antagonist SR 142948A on 3,4-methylenedioxymethamphetamine-induced behaviours in mice. *Neuropharmacology*, **2008**, 54, 1107-11	5.5	14
57	Kainic acid down-regulates NOP receptor density and gene expression in human neuroblastoma SH-SY5Y cells. *Journal of Molecular Neuroscience*, **2008**, 35, 171-7	3.3	6
56	Alterations of CREB and DARPP-32 phosphorylation following cocaine and monoaminergic uptake inhibitors. *Brain Research*, **2007**, 1128, 33-9	3.7	6

55	Role of serotonin in the regulation of the dynorphinergic system by a kappa-opioid agonist and cocaine treatment in rat CNS. *Neuroscience*, **2007**, 144, 157-64	3.9	12
54	The kappa-opioid receptor agonist U-69593 prevents cocaine-induced phosphorylation of DARPP-32 at Thr(34) in the rat brain. *Brain Research Bulletin*, **2007**, 73, 34-9	3.9	7
53	Chronic cocaine produces decreases in N/OFQ peptide levels in select rat brain regions. *Journal of Molecular Neuroscience*, **2007**, 31, 159-64	3.3	11
52	Nociceptin levels in the cerebrospinal fluid of chronic pain patients with or without intrathecal administration of morphine. *Journal of Pain and Symptom Management*, **2006**, 32, 372-7	4.8	24
51	Alterations in prodynorphin gene expression and dynorphin levels in different brain regions after chronic administration of 14-methoxymetopon and oxycodone-6-oxime. *Brain Research Bulletin*, **2006**, 70, 233-9	3.9	14
50	Chronic and acute effects of 3,4-methylenedioxy-N-methylamphetamine (‘ecstasy’) administration on the dynorphinergic system in the rat brain. *Neuroscience*, **2006**, 137, 187-96	3.9	16
49	Effects of prolonged treatment with the opiate tramadol on prodynorphin gene expression in rat CNS. *Journal of Molecular Neuroscience*, **2006**, 30, 341-7	3.3	14
48	Nociceptin/orphanin FQ prevents the antinociceptive action of paracetamol on the rat hot plate test. *European Journal of Pharmacology*, **2005**, 507, 43-8	5.3	12
47	Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson’s disease. *Journal of Neuroscience*, **2005**, 25, 9591-601	6.6	105
46	Kainate seizures increase nociceptin/orphanin FQ release in the rat hippocampus and thalamus: a microdialysis study. *Journal of Neurochemistry*, **2004**, 91, 30-7	6	27
45	Role of serotonin on cocaine-mediated effects on prodynorphin gene expression in the rat brain. *Journal of Molecular Neuroscience*, **2004**, 22, 213-22	3.3	14
44	Differential time course of effects of kappa-opioid agonist treatment on dynorphin A levels and kappa-opioid receptor density. *Journal of Molecular Neuroscience*, **2004**, 24, 307-14	3.3	6
43	Effects of the selective norepinephrine uptake inhibitor nisoxetine on prodynorphin gene expression in rat CNS. *Molecular Brain Research*, **2004**, 127, 115-20		10
42	Involvement of the neuropeptide nociceptin/orphanin FQ in kainate seizures. *Journal of Neuroscience*, **2002**, 22, 10030-8	6.6	35
41	Involvement of the neuropeptide orphanin FQ/nociceptin in kainate and kindling seizures and epileptogenesis. *Epilepsia*, **2002**, 43 Suppl 5, 18-9	6.4	15
40	Modulation of proorphaninFQ/N gene expression by morphine in the rat mesocorticolimbic system. *NeuroReport*, **2002**, 13, 645-8	1.7	12
39	Regulation of dynorphin gene expression by kappa-opioid agonist treatment. *NeuroReport*, **2002**, 13, 107-9	1.7	13
38	The effect of a paracetamol and morphine combination on dynorphin A levels in the rat brain. *Biochemical Pharmacology*, **2001**, 61, 1409-16	6	14

37	Chronic GBR 12909 administration differentially alters prodynorphin gene expression compared to cocaine. *European Journal of Pharmacology*, **2001**, 413, 207-12	5.3	16
36	The effect of paracetamol on nociception and dynorphin A levels in the rat brain. *Neuropeptides*, **2001**, 35, 110-6	3.3	25
35	Some new 1,2,3,4-tetrahydroquinoline derivatives. *Il Farmaco*, **2000**, 55, 47-50		0
34	Supraspinal and spinal effects of [Phe1psi(CH2-NH)Gly2]-nociceptin(1-13)-NH2 on nociception in the rat. *Life Sciences*, **2000**, 66, 257-64	6.8	19
33	Region-specific changes in prodynorphin mRNA and ir-dynorphin A levels after kindled seizures. *Journal of Molecular Neuroscience*, **1999**, 13, 69-75	3.3	9
32	Methamphetamine alters prodynorphin gene expression and dynorphin A levels in rat hypothalamus. *European Journal of Pharmacology*, **1999**, 365, 183-6	5.3	9
31	Limbic seizures increase pronociceptin mRNA levels in the thalamic reticular nucleus. *NeuroReport*, **1999**, 10, 541-6	1.7	15
30	Chronic intracerebroventricular cocaine differentially affects prodynorphin gene expression in rat hypothalamus and caudate-putamen. *Molecular Brain Research*, **1996**, 40, 153-6		28
29	Dynorphin and epilepsy. *Progress in Neurobiology*, **1996**, 50, 557-83	10.9	74
28	Kindled seizure-induced c-fos and prodynorphin mRNA expressions are unrelated in the rat brain. *European Journal of Neuroscience*, **1996**, 8, 2064-7	3.5	15
27	Long-term exposure to opioid antagonists up-regulates prodynorphin gene expression in rat brain. *Brain Research*, **1995**, 672, 42-7	3.7	20
26	Early changes in prodynorphin mRNA and ir-dynorphin A levels after kindled seizures in the rat. *European Journal of Neuroscience*, **1995**, 7, 1850-6	3.5	22
25	Opioid antagonists up-regulate prodynorphin gene expression in rat brain. *Regulatory Peptides*, **1994**, 53, S145-S146		2
24	Binding profile of benextramine at neuropeptide Y receptor subtypes in rat brain areas. *European Journal of Pharmacology*, **1994**, 265, 93-8	5.3	11
23	Regulation of opioid gene expression by and opiate agonists. *Pharmacological Research*, **1992**, 25, 264-265	10.2	1
22	Alterations in vasoactive intestinal polypeptide-related peptides after pentylenetetrazole-induced seizures in rat brain. *European Journal of Pharmacology*, **1992**, 229, 149-53	5.3	16
21	Substance P is diminished and vasoactive intestinal peptide is augmented in psoriatic lesions and these peptides exert disparate effects on the proliferation of cultured human keratinocytes. *Journal of Investigative Dermatology*, **1992**, 98, 421-7	4.3	101
20	Substance P levels are decreased in lesional skin of atopic dermatitis. *Experimental Dermatology*, **1992**, 1, 127-8	4	28

19	Skin levels of vasoactive intestinal polypeptide in atopic dermatitis. *Archives of Dermatological Research*, **1991**, 283, 230-2	3.3	26
18	Chronic opiate agonists down-regulate prodynorphin gene expression in rat brain. *Brain Research*, **1991**, 563, 132-6	3.7	54
17	The opioid antagonist naloxone influences prodynorphin gene expression. *Pharmacological Research*, **1990**, 22 Suppl 1, 111-2	10.2	
16	Distribution and characterization of VIP-related peptides in the rat spinal cord. *Neuropeptides*, **1990** , 16, 219-25	3.3	4
15	Chronic exposure to opioid agonists and antagonists affects prodynorphin gene expression. *Acta Physiologica Hungarica*, **1990**, 75 Suppl, 247-8		
14	Morphine affects prodynorphin gene expression in some areas of rat brain. *Annali Dellistituto Superiore Di Sanita*, **1990**, 26, 43-6	1.6	4
13	An opiate chronic treatment affects prodynorphingene expression. *Pharmacological Research*, **1989** , 21, 477-478	10.2	4
12	Vasoactive intestinal polypeptide carboxy-terminal fragment, VIP(22-28), and other fragments of VIP, in the central nervous system of the rat. *Peptides*, **1989**, 10, 621-6	3.8	6
11	Interplay between VIP and serotonergic system in rat CNS. *Pharmacological Research Communications*, **1988**, 20, 329		1
10	Evidence for the presence of VIP 2228 heptapeptide in rat brain cortex. *Pharmacological Research Communications*, **1988**, 20, 35-36		1
9	Distinguishable effects of intrathecal dynorphins, somatostatin, neurotensin and s-calcitonin on nociception and motor function in the rat. *Pain*, **1988**, 35, 95-104	8	45
8	Regional distribution of immunoreactive dynorphin A in the human gastrointestinal tract. *Neuropeptides*, **1988**, 11, 101-5	3.3	16
7	Protection by opioids against gastric lesions caused by necrotizing agents. *Pharmacology*, **1988**, 36, 140-4	4.3	20
6	Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract of Cannabis sativa L. *Psychopharmacology*, **1986**, 89, 244-7	4.7	16
5	Studies on the antinociceptive effect of intrathecal salmon calcitonin. *Peptides*, **1985**, 6 Suppl 3, 273-6	3.8	32
4	Possible involvement of dynorphinergic system in nociceptive transmission at spinal level. *Neuropeptides*, **1985**, 5, 425-8	3.3	6
3	Antinociceptive activity of salmon calcitonin injected intrathecally in the rat. *Neuroscience Letters*, **1984**, 45, 135-9	3.3	30
2	Effects of hypothalamic lesions on the content of dynorphin immunoreactivity in pituitary. *Life Sciences*, **1983**, 33 Suppl 1, 503-6	6.8	7

1	Current and Future Therapeutic Options In Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation. *CNS Drugs*,	6.7	0